Literature DB >> 15808464

Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.

Christopher D Cox1, Michael J Breslin, Brenda J Mariano, Paul J Coleman, Carolyn A Buser, Eileen S Walsh, Kelly Hamilton, Hans E Huber, Nancy E Kohl, Maricel Torrent, Youwei Yan, Laurence C Kuo, George D Hartman.   

Abstract

Optimization of high-throughput screening (HTS) hits resulted in the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of KSP. Dihydropyrazole 15 is a potent, cell-active KSP inhibitor that induces apoptosis and generates aberrant mitotic spindles in human ovarian carcinoma cells at low nanomolar concentrations. X-ray crystallographic evidence is presented which demonstrates that these inhibitors bind in an allosteric pocket of KSP distant from the nucleotide and microtubule binding sites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808464     DOI: 10.1016/j.bmcl.2005.02.055

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

1.  A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.

Authors:  Hanna Jean Khoury; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Maria Cielo Foudray; Martha Arellano; Amelia Langston; Beverly Bethelmie-Bryan; Selena Rush; Kevin Litwiler; Sharon Karan; Heidi Simmons; Adam I Marcus; Mieke Ptaszynski; Hagop Kantarjian
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

2.  Allosteric drug discrimination is coupled to mechanochemical changes in the kinesin-5 motor core.

Authors:  Elizabeth D Kim; Rebecca Buckley; Sarah Learman; Jessica Richard; Courtney Parke; David K Worthylake; Edward J Wojcik; Richard A Walker; Sunyoung Kim
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

3.  Solution-phase parallel synthesis of a library of delta(2)-pyrazolines.

Authors:  Shankar Manyem; Mukund P Sibi; Gerald H Lushington; Benjamin Neuenswander; Frank Schoenen; Jeffrey Aubé
Journal:  J Comb Chem       Date:  2007 Jan-Feb

4.  Getting in sync with dimeric Eg5. Initiation and regulation of the processive run.

Authors:  Troy C Krzysiak; Michael Grabe; Susan P Gilbert
Journal:  J Biol Chem       Date:  2007-11-25       Impact factor: 5.157

5.  Docking studies on kinesin spindle protein inhibitors: an important cooperative 'minor binding pocket' which increases the binding affinity significantly.

Authors:  Cheng Jiang; Yadong Chen; Xiaojian Wang; Qidong You
Journal:  J Mol Model       Date:  2007-06-23       Impact factor: 1.810

6.  Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site.

Authors:  Ksenia Oguievetskaia; Laetitia Martin-Chanas; Artem Vorotyntsev; Olivia Doppelt-Azeroual; Xavier Brotel; Stewart A Adcock; Alexandre G de Brevern; Francois Delfaud; Fabrice Moriaud
Journal:  J Comput Aided Mol Des       Date:  2009-06-17       Impact factor: 3.686

7.  ATPase mechanism of Eg5 in the absence of microtubules: insight into microtubule activation and allosteric inhibition by monastrol.

Authors:  Jared C Cochran; Susan P Gilbert
Journal:  Biochemistry       Date:  2005-12-20       Impact factor: 3.162

8.  Cinchona alkaloid catalyzed enantioselective amination of α,β-unsaturated ketones: an asymmetric approach to Δ2-pyrazolines.

Authors:  Nathaniel R Campbell; Bingfeng Sun; Ravi P Singh; Li Deng
Journal:  Adv Synth Catal       Date:  2011-11-01       Impact factor: 5.837

9.  NSC 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site.

Authors:  Sarah S Learman; Catherine D Kim; Nathaniel S Stevens; Sunyoung Kim; Edward J Wojcik; Richard A Walker
Journal:  Biochemistry       Date:  2009-03-03       Impact factor: 3.162

Review 10.  A medicinal chemist's guide to molecular interactions.

Authors:  Caterina Bissantz; Bernd Kuhn; Martin Stahl
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.